Antifungal Drug Market - Global Industry Analysis

Antifungal Drug Market- By Drug Type (Echinocandins, Azoles, Polyenes, and Allylamines), By Indication (Aspergillosis, Dermatophytosis, and Candidiasis), By Dosage Form (Powder, Ointments, and Tablets), and By Distribution Channel (Hospital Pharmacies and Retail Pharmacies & Drug Stores): Global Industry Perspective, Comprehensive Analysis, And Forecast, 2022–2028

Published Date: 14-Mar-2022 Category: Pharmaceutical Report Format : PDF Pages: 190 Report Code: ZMR-534 Status : Published

The global Antifungal Drug Market accrued earnings worth approximately 15.1 (USD Billion) in 2021 and is predicted to gain revenue of about 20.23 (USD Billion) by 2028, is set to record a CAGR of nearly 3.7% over the period from 2022 to 2028.

Description

The global Antifungal Drug Market accrued earnings worth approximately 15.1 (USD Billion) in 2021 and is predicted to gain revenue of about 20.23 (USD Billion) by 2028, is set to record a CAGR of nearly 3.7% over the period from 2022 to 2028. The study provides assessment and analysis of the Antifungal Drug Market on a global & regional level. It offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2021 along with a forecast from 2022 to 2028 based on revenue (USD Billion).

COVID Impact Analysis On Antifungal Drug Market

Outbreak of pandemic has restricted expansion of size of antifungal market and is likely to continue even in next few years. Reportedly, rapid spread of SARS-CoV-2 virus has not only hampered economy of nation, but also severely affected various business including pharmaceutical businesses like antifungal drug sales. With increase in lockdown period for restricting spread of pandemic and strict government measures limiting movement of persons from one place to another has affected supply chain activities, thereby posing a threat to sale of antifungal drugs.  

Antifungal Drug Market: Outlook

Invasive fungal infections are a key cause of mortality in immune-compromised patients and this has proved to be economic burden on healthcare sector across globe. As per NCBI, these infections have caused nearly 2 million fatalities each year. Moreover, recent antifungal drugs have proved to be less clinically efficient and new antifungal agents along with new combination regimens as well as new drug formulations for improving patient care will drive market trends. Furthermore, antifungal drugs eradicate pathogens from hosts with minimal side-effects. In addition to this, launching of novel antifungal medicines such as echinocandins and second-generation triazoles in last few years has favorably influenced managing of invasive mycoses in a way that drug toxicity has become less vital factor in drug treatment of fungal infections.

Additionally, antifungal drugs are also referred to as antimycotic drugs and it is a fungistatic utilized for treating mycosis including ringworm, athlete’s foot, cryptococcal meningitis, and candidiasis. Anti-fungal drugs can be bifurcated into three types, namely, azoles that inhibit ergosterol synthesis, polyenes which interacts with fungal membrane sterols physio-chemically, and 5-flurocystosine that obstruct macromolecular synthesis.

Global Antifungal Drug Market

Antifungal Drug Market: Growth Drivers

Occurrence of fungal infections in immune-compromised patients such as AIDS, cancer patients, and individuals affected due to autoimmune disorders will offer new growth avenues for antifungal drug industry. Surge in use of nanotechnology in formulation of advanced antifungal medicines will impel expansion of antifungal drug industry. A prominent increase in nosocomial infections in patients will spearhead demand for antifungal drugs in healthcare sector. Nonetheless, use of conventional medicines can hinder growth of antifungal drug industry.

Furthermore, increase in awareness about fungal infections and surge in drug demand for countering chronic fungal diseases will steer penetration of antifungal drugs in healthcare sector. This will spur increase in size of antifungal drug market. Innovations in drug development and huge investment of drug research activities will prompt expansion of antifungal drug market.

Antifungal Drug Market: Regional Landscape

North America To Account Substantially Towards Regional Market Share By 2028

Growth of antifungal drug industry in North America over forecast timespan is owing to surge in use of novel antifungal drugs for treating fungal infections. For instance, in December 2020, the U.S. FDA approved application of Scynexis Inc. for its drug ibrexafungerp that has ability for treating vaginal yeast infection. Apart from this, rise in funding of research work related to new antifungal drugs will expand scope of antifungal drug market in years to come.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Competitive Insights

Key players have majorly influenced growth of antifungal drug market and will continue to do so even in next couple of years. They are Asperqillus, Abbott Laboratories, Alternaria, Enzon Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Glaxosmithkline plc, Bayer Healthcare, Novartis AG, Sanofi S.A., Kramer Laboratories, and Gilead Sciences, Inc.

The global Antifungal Drug Market is segmented as follows:

By Drug Type

  • Echinocandins
  • Azoles
  • Polyenes
  • Allylamines

By Indication

  • Aspergillosis
  • Dermatophytosis
  • Candidiasis

 By Dosage Form

  • Powder
  • Ointments
  • Tablets

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France 
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Antifungal Drug Market, 2016-2026 (USD Billion)
    • 2.2. Antifungal Drug Market: Snapshot
  • Chapter 3. Antifungal Drug Market - Industry Analysis
    • 3.1. Antifungal Drug Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Rapid Spread Of Fungal Infection
      • 3.2.2. Pandemicity Of Fungal Infection
    • 3.3. Restraints
      • 3.3.1. High Penetration Of Conventional Drugs
    • 3.4. Opportunity
      • 3.4.1. Covering Untapped Market
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Drug Type
      • 3.6.2. Market attractiveness analysis By Dosage Form
      • 3.6.3. Market attractiveness analysis By Therapeutic Indication
      • 3.6.4. Market attractiveness analysis by Region
  • Chapter 4. Antifungal Drug Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Antifungal Drug Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Drug Type launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Antifungal Drug Market -Drug Type Analysis
    • 5.1. Global Antifungal Drug Market overview: By Drug Type type
      • 5.1.1. Global Antifungal Drug Market share, By Drug Type,2019 and 2026
    • 5.2. Echinocandins
      • 5.2.1. Global Antifungal Drug Market by Echinocandins, 2016-2026 (USD Billion)
    • 5.3. Azoles
      • 5.3.1. Global Antifungal Drug Market by Azoles, 2016-2026 (USD Billion)
    • 5.4. Ployenes
      • 5.4.1. Global Antifungal Drug Market by Ployenes, 2016-2026 (USD Billion)
    • 5.5. Allylamines
      • 5.5.1. Global Antifungal Drug Market by Allylamines, 2016-2026 (USD Billion)
    • 5.6. Others
      • 5.6.1. Global Antifungal Drug Market by others, 2016-2026 (USD Billion)
  • Chapter 6. Global Antifungal Drug Market -Dosage Form Analysis
    • 6.1. Global Antifungal Drug Market overview: By Dosage Form
      • 6.1.1. Global Antifungal Drug Market share, By Dosage Form, 2019 and 2026
    • 6.2. Powders
      • 6.2.1. Global Antifungal Drug Market By Powders, 2016-2026 (USD Billion)
    • 6.3. Ointments
      • 6.3.1. Global Antifungal Drug Market By Ointments, 2016-2026 (USD Billion)
    • 6.4. Drugs
      • 6.4.1. Global Antifungal Drug Market By Drugs, 2016-2026 (USD Billion)
    • 6.5. Pastes
      • 6.5.1. Global Antifungal Drug Market By Pastes, 2016-2026 (USD Billion)
  • Chapter 7. Global Antifungal Drug Market -Therapeutic Indication Analysis
    • 7.1. Global Antifungal Drug Market overview: By Therapeutic Indication
      • 7.1.1. Global Antifungal Drug Market share, By Therapeutic Indication, 2019 and 2026
    • 7.2. Aspergillosis
      • 7.2.1. Global Antifungal Drug Market by Aspergillosis, 2016-2026 (USD Billion)
    • 7.3. Dermatophytosis
      • 7.3.1. Global Antifungal Drug Market by Dermatophytosis, 2016-2026 (USD Billion)
    • 7.4. Candidiasis
      • 7.4.1. Global Antifungal Drug Market by Candidiasis, 2016-2026 (USD Billion)
    • 7.5. Others
      • 7.5.1. Global Antifungal Drug Market by others, 2016-2026 (USD Billion)
  • Chapter 8. Global Antifungal Drug Market - Regional Analysis
  • 8.1. Global Antifungal Drug Market overview: by Region
    • 8.1.1. Global Antifungal Drug Marketshare, by Region, 2019 and 2026
  • 8.2. North America
    • 8.2.1. North America Antifungal Drug Market, 2016-2026 (USD Billion)
    • 8.2.2. North America Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
    • 8.2.3. North America Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
    • 8.2.4. North America Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
    • 8.2.5. The U.S.
      • 8.2.5.1. The U.S.Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
      • 8.2.5.2. The U.S.Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
      • 8.2.5.3. The U.S.Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
    • 8.2.6. Rest of North America
      • 8.2.6.1. Rest of North America Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
      • 8.2.6.2. Rest of North America Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
      • 8.2.6.3. Rest of North America Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Antifungal Drug Market, 2016-2026 (USD Billion)
    • 8.3.2. Europe Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
    • 8.3.3. Europe Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
    • 8.3.4. Europe Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
    • 8.3.5. UK
      • 8.3.5.1. U.K.Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
      • 8.3.5.2. U.K.Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
      • 8.3.5.3. U.K. Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
    • 8.3.6. France
      • 8.3.6.1. France Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
      • 8.3.6.2. France Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
      • 8.3.6.3. France Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
    • 8.3.7. Germany
      • 8.3.7.1. Germany Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
      • 8.3.7.2. Germany Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
      • 8.3.7.3. Germany Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
    • 8.3.8. Rest of Europe
      • 8.3.8.1. Rest of EuropeAntifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
      • 8.3.8.2. Rest of EuropeAntifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
      • 8.3.8.3. Rest of Europe Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Antifungal Drug Market, 2016-2026 (USD Billion)
    • 8.4.2. Asia Pacific Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
    • 8.4.3. Asia Pacific Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
    • 8.4.4. Asia Pacific Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
    • 8.4.5. China
      • 8.4.5.1. China Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
      • 8.4.5.2. China Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
      • 8.4.5.3. China Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
    • 8.4.6. Japan
      • 8.4.6.1. Japan Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
      • 8.4.6.2. Japan Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
      • 8.4.6.3. Japan Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
    • 8.4.7. India
      • 8.4.7.1. India Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
      • 8.4.7.2. India Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
      • 8.4.7.3. India Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
    • 8.4.8. Rest of Asia Pacific
      • 8.4.8.1. Rest of Asia Pacific Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
      • 8.4.8.2. Rest of Asia Pacific Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
      • 8.4.8.3. Rest of Asia Pacific Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Antifungal Drug Market, 2016-2026 (USD Billion)
    • 8.5.2. Latin America Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
    • 8.5.3. Latin America Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
    • 8.5.4. Latin America Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
    • 8.5.5. Brazil
      • 8.5.5.1. Brazil Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
      • 8.5.5.2. Brazil Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
      • 8.5.5.3. Brazil Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
    • 8.5.6. Rest of LatinAmerica
      • 8.5.6.1. Rest of LatinAmerica Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
      • 8.5.6.2. Rest of LatinAmerica Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
      • 8.5.6.3. Rest of Latin America Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
  • 8.6. The Middle East and Africa
    • 8.6.1. The Middle East and Africa Antifungal Drug Market, 2016-2026 (USD Billion)
    • 8.6.2. The Middle East and Africa Antifungal Drug Market revenue, By Drug Type,2016-2026 (USD Billion)
    • 8.6.3. The Middle East and Africa Antifungal Drug Market revenue, By Dosage Form, 2016-2026 (USD Billion)
    • 8.6.4. The Middle East and Africa Antifungal Drug Market revenue, By Therapeutic Indication, 2016-2026 (USD Billion)
  • Chapter 9. Company Profiles
    • 9.1. Asperqillus
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Drug Type Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. Alternaria
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Drug Type Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. Abbott Laboratories
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Drug Type Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. Pfizer
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Drug Type Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. Glaxosmithkline
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Drug Type Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Development
    • 9.6. Bayer Healthcare
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Drug Type Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Development
    • 9.7. Novartis
      • 9.7.1. Overview
      • 9.7.2. Financials
      • 9.7.3. Drug Type Portfolio
      • 9.7.4. Business Strategy
      • 9.7.5. Recent Development
    • 9.8. Sanofi-Aventis
      • 9.8.1. Overview
      • 9.8.2. Financials
      • 9.8.3. Drug Type Portfolio
      • 9.8.4. Business Strategy
      • 9.8.5. Recent Development
    • 9.9. Merck & Co.
      • 9.9.1. Overview
      • 9.9.2. Financials
      • 9.9.3. Drug Type Portfolio
      • 9.9.4. Business Strategy
      • 9.9.5. Recent Development
    • 9.10. Kramer Laboratories
      • 9.10.1. Overview
      • 9.10.2. Financials
      • 9.10.3. Drug Type Portfolio
      • 9.10.4. Business Strategy
      • 9.10.5. Recent Development

Table Of Figures

List of Figures

1. Market research process
2. Market research methodology
3. Global Antifungal Drug Market, 2016–2026 (USD Billion)
4. Porter’s Five Forces Analysis
5. Global Antifungal Drug Market attractiveness, By Drug Type type
6. Global Antifungal Drug Market attractiveness, By Dosage Form
7. Global Antifungal Drug Market attractiveness, By Therapeutic Indication
8. Global Antifungal Drug Marketmarket share, By Drug Type, 2019 and 2026
9. Global Antifungal Drug Market by Echinocandins, 2016–2026 (USD Billion)
10. Global Antifungal Drug Market by Azoles,2016–2026 (USD Billion)
11. Global Antifungal Drug Market by Ployenes,2016–2026 (USD Billion)
12. Global Antifungal Drug Market by Allylamines,2016–2026 (USD Billion)
13. Global Antifungal Drug Market by Others,2016–2026 (USD Billion)
14. Global Antifungal Drug Market share, By Dosage Form, 2019 and 2026
15. Global Antifungal Drug Market By Powders, 2016–2026 (USD Billion)
16. Global Antifungal Drug Market By Ointments, 2016–2026 (USD Billion)
17. Global Antifungal Drug Market By Drugs, 2016–2026 (USD Billion)
18. Global Antifungal Drug Market By Pastes, 2016–2026 (USD Billion)
19. Global Antifungal Drug Market share, By Therapeutic Indication, 2019 and 2026
20. Global Antifungal Drug Market by Aspergillosis, 2016–2026 (USD Billion)
21. Global Antifungal Drug Market by Dermatophytosis, 2016–2026 (USD Billion)
22. Global Antifungal Drug Market by Candidiasis, 2016–2026 (USD Billion)
23. Global Antifungal Drug Market by Others, 2016–2026 (USD Billion)
24. Global Antifungal Drug Market share, by Region, 2019and 2026
25. North America Antifungal Drug Market, 2016–2026 (USD Billion)
26. Europe Antifungal Drug Market, 2016–2026 (USD Billion)
27. Asia Pacific Antifungal Drug Market, 2016–2026 (USD Billion)
28. Latin America Antifungal Drug Market, 2016–2026 (USD Billion)
29. The Middle East and Africa Antifungal Drug Market, 2016–2026 (USD Billion)


Table Of Tables

List of Tables

1. Global Antifungal Drug Market: snapshot
2. Drivers of theAntifungal Drug Market: impact analysis
3. Restraints of theAntifungal Drug Market: impact analysis
4. North America Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
5. North America Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
6. North America Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
7. The U.S. Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
8. The U.S. Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
9. The U.S. Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
10. Rest of North America Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
11. Rest of North America Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
12. Rest of North America Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
13. Europe Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
14. Europe Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
15. Europe Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
16. U.K.Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
17. U.K.Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
18. U.K. Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
19. France Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
20. France Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
21. France Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
22. Germany Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
23. Germany Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
24. Germany Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
25. Rest of EuropeAntifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
26. Rest of EuropeAntifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
27. Rest of Europe Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
28. Asia Pacific Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
29. Asia Pacific Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
30. Asia Pacific Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
31. China Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
32. China Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
33. China Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
34. Japan Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
35. Japan Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
36. Japan Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
37. India Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
38. India Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
39. India Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
40. Rest of Asia Pacific Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
41. Rest of Asia Pacific Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
42. Rest of Asia Pacific Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
43. Latin America Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
44. Latin America Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
45. Latin America Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
46. Brazil Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
47. Brazil Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
48. Brazil Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
49. Rest of Latin America Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
50. Rest of Latin America Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
51. Rest of Latin America Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)
52. The Middle East and Africa Antifungal Drug Market revenue, By Drug Type,2016–2026 (USD Billion)
53. The Middle East and Africa Antifungal Drug Market revenue, By Dosage Form, 2016–2026 (USD Billion)
54. The Middle East and Africa Antifungal Drug Market revenue, By Therapeutic Indication, 2016–2026 (USD Billion)

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Antifungal Drug market. Zion Research has collected and analyzed key data belong to the global Antifungal Drug market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Antifungal Drug across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Antifungal Drug industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Antifungal Drug market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Fungi are a diverse group of microorganisms that have modified themselves to remain alive in a wide array of environments. These environments may vary from the human body to discrete areas of nature. Fungi can produce diverse human infections ranging from superficial skin infections to internal organ invasion in the body. These viable infections usually happen due to decrease in natural human defenses/immune system or due to heavy exposure to the fungus. Selection of   therapies for treating fungal infections based on the type of infection or type of fungus involved in infection. Topical/superficial infections are usually treated with topical agents whereas peripheral infection is treated with systemic therapy.

Globally, antifungal drug market has been accelerated due to continuous rise in percentage of fungal infections specially the ringworm infection. Furthermore, lack of awareness coupled with self-medication is considered as major key factors which are expected to promote the growth of antifungal drug market. Moreover many lifestyle-related factors, such as sedentary lifestyle, eating junk food which may leads to weaken the immune system and thus promote the fungal growth. However, high penetration of conventional drugs is key restraining factor for the growth of anti-fungal drug market. Nonetheless, ongoing research and development in prevention and treatment of fungal infection like to bring growth avenues nearby future.

Based on drug type, the global market of antifungal drug is bifurcated into five types: echinocandins, azoles, ployenes, allylamines and others. Azoles are systemically acting antifungal drug which include fluconazole, itraconazole, ketoconazole, posaconazole and voriconazole. The echinocandins are lipopeptides derived from natural fungal fermentation products. They include anidulafungin, caspofungin and micafungin. Azole derivative was the leading derivatives in term of generating revenue in 2019 and this growth is expected to continue within the forecast period. The growth is attributed due to effective price and fungicidal properties of azole derivatives like ketokonazole, itaconazole etc.

Based on therapeutic indication, the global market of antifungal drug is bifurcated into four types: aspergillosis, dermatophytosis, candidiasis and others. The most commonly encountered fungal infections are those that affect the skin layers. Approximately 1-2% of the world’s population is affected by dermatophytoses (superficial fungal infections of the skin). Seborric dermatisis, ringworm infection, jock itch are the examples of various topical fungal infections.

Based on dosage form, the global market of antifungal drug is bifurcated into four types: powders, ointments, drugs and pastes. Over the counter antifungal drugs like clo-trimoxazole (sulphamethoxazole + trimethoprim) are available in powder, ointment form and can be easily obtained without doctor/physician prescriptions. Whereas, majority of the oral antifungal drugs are prescription based medicines and are available in various dosage forms such as tablets, capsules and suspensions. Powder, ointment is covering approximately more than 55% of antifungal drug market.

Based on geographies, the global market of antifungal drug is bifurcated into five types: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. These segments are further bifurcated into the U.S., UK, Germany, France, China, Japan, India and Brazil. North America accounted for the largest share of the global antifungal market, followed by Europe. This growth is attributed due to rising awareness related to health care in this region. Moreover, antifungal drug market has huge opportunity in the emerging markets of Asia Pacific region due to increasing standard of living, large pool of patient in this region. The Asia-Pacific market is projected to grow at the highest CAGR during the forecast period, due to the rising incidence of fungal infection, increasing government support and growing upper middle-class population and rise in disposable income level in this region. Understanding the rising episodes of fungal infections in the country, the government employed various measures on its own including public private partnership (PPP). This development is largely responsible for propelling the Indian market of antifungal drug.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global antifungal drug market include Asperqillus, Alternaria, Abbott Laboratories, Pfizer, Glaxosmithkline, Bayer Healthcare, Novartis, Sanofi-Aventis, Merck & Co., Kramer Laboratories, Enzon Pharmaceuticals, and Gilead.

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

Occurrence of fungal infections in immune-compromised patients such as AIDS, cancer patients, and individuals affected due to autoimmune disorders will offer new growth avenues for antifungal drug industry.   

According to Zion market research report, The global Antifungal Drug Market accrued earnings worth approximately 15.1 (USD Billion) in 2021 and is predicted to gain revenue of about 20.23 (USD Billion) by 2028, is set to record a CAGR of nearly 3.7% over the period from 2022 to 2028.

North America will contribute lucratively towards the global market earnings over the projected timeline. The regional market surge is subject to surge in use of novel antifungal drugs for treating fungal infections in sub-continent.     

The key market participants leveraging business sphere include Asperqillus, Abbott Laboratories, Alternaria, Enzon Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Glaxosmithkline plc, Bayer Healthcare, Novartis AG, Sanofi S.A., Kramer Laboratories, and Gilead Sciences, Inc.

 

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed